Modern approach to optimizing antiarrhythmic therapy. Possibilities of ethylmethylhydroxypyridine succinate

Modern approach to optimizing antiarrhythmic therapy. Possibilities of ethylmethylhydroxypyridine succinate

V.P. Mikhin, T.A. Nikolenko, V.V. Savelyeva, M.A. Chernyatina

Kursk State Medical University, Kursk

The issue concerning the association between chronic coronary syndrome and cardiac arrhythmias, despite its relative study, remains of high priority for modern medicine. Certain limitations for the use of antiarrhythmic drugs in this patient cohort require continued improvement of pharmacotherapy regimens, including pathogenetically justified ones. Ethylmethylhydroxypyridine succinate (EMHPS) is one of the promising components of antiarrhythmic therapy in patients with coronary heart disease. The presented review systematizes the study results proving its efficacy, taking into account the clinical use of the Mexicor (domestic drug). Thus, the EMHPS use in patients with cardiac arrhythmias has significantly reduced the number of ventricular extrasystoles (by 2.8 times), including high gradations (by 3 times). The combination of Mexicor with Metoprolol allowed to significantly (by more than 20%) increase the antiarrhythmic activity of the β-adrenoblocker. EMHPS has shown sufficient efficacy in terms of normalizing the electrical stability in patients with cardiovascular diseases after myocardial infarction and postcovid period, as well as as a drug that reduces the risk of atrial fibrillation recurrence after pulmonary vein isolation by radiofrequency ablation (by 45% in the first month of therapy). The antiarrhythmic effect of EMHPS is reproduced in independent studies and can be easily confirmed by objective diagnostic tests (electrocardiography, Holter monitor, positron emission tomography).

Keywords: cardiac arrhythmia, coronary heart disease, ventricular extrasystole, ethylmethylhydroxypyridine succinate, Mexicor.

For citation: Mikhin V.P., Nikolenko T.A., Savelyeva V.V., Chernyatina M.A. Modern approach to optimizing antiarrhythmic therapy. Possibilities of ethylmethylhydroxypyridine succinate. RMJ. 2023;9:35–39.